Arch Biopartners has announced that Catalent Inhalation will begin the process of manufacturing its AB569 bactericidal inhalation solution for use in trials of the drug in patients with antibiotic resistant lung infections. The process will start with formulation and stability studies and then move on to manufacture of clinical trial supplies, the company said.
AB569, which is in development for the treatment of P. aeruginosa lung infections in CF patients, has received orphan drug designation in both the US and the EC.
Catalent VP and General Manager for Advanced Delivery Technologies Jonathan Arnold commented, “We are pleased to support Arch Biopartners’ program from our recently expanded facility in Morrisville, North Carolina, Catalent’s Centre of Excellence in the development and manufacture of inhaled dose forms.”
Read the Arch Biopartners press release.
